News
Zacks.com on MSN20h
PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last?
With the end of the pandemic, sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, have declined from their peak. However, Pfizer’s non-COVID operational revenues are improving, driven by its ...
Zacks Investment Research on MSN2h
Exelixis Gains 15.6% YTD: How Should You Play the Stock?
Exelixis’ EXEL year-to-date performance has been good. Shares of the biotech company have gained 15.6% compared with the ...
During a live event, Nataliya Mar, MD, discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback